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EXECUTIVE SUMMARY
PURPOSE
This report provides suggested toxicity guidelines for assessment and selection of chemical protective
ensembles (CPEs) to be used by civilian and military first responders operating in a chemical warfare
agent vapor environment. The agents evaluated include the G-series and VX nerve agents, the vesicant
sulfur mustard (agent HD) and, to a lesser extent, the vesicant Lewisite (agent L). The focus of this
evaluation is percutaneous vapor permeation of CPEs and resulting skin absorption. A critical
assumption underlying this evaluation is that first responders in an agent vapor atmosphere will be
wearing self-contained breathing apparatus (SCBA) with full-face protection, and are thus adequately
protected against inhalation or direct eye vapor exposure. Specific recommendations regarding toxicity
criteria for SCBA/full-face protection are not addressed by this report. Exposures to liquids, aerosols,
mixtures, or multiple agents are not addressed by this evaluation.
This analysis focused on estimating acceptable levels of chemical agent vapor permeation through a
protective suit that would provide adequate health protection. The resulting toxicity guidelines are not
intended to be the sole criteria from which to assess or select specific CPEs. This assessment notes that
numerous other criteria are important to appropriate ensemble selection; for example, the CPE must
also exhibit sufficient tear strength and flexibility, and meet other requirements critical to maintaining
conduct of operations and mission capability. This assessment acknowledges the significance of these
other necessary parameters that must also be factored into CPE selection.
KEY CONCLUSIONS
 Percutaneous vapor concentrations needed to produce adverse effects are significantly greater
than inhalation vapor concentrations necessary to produce the same effect (for nerve agents
especially, and sulfur mustard to a lesser extent). Thus, health-based inhalation and ocular toxicity
guidelines used to test adequacy of respiratory protection would be substantially protective for
percutaneous vapor effects from the same agent exposure. However, use of overly
protective inhalation and ocular toxicity criteria for CPE evaluation may unnecessarily limit
consideration of other critical CPE operational specifications. Application of separate vapor
toxicity guidelines for percutaneous vapor absorption alone will ensure that CPE testing criteria
include an appropriate balance of protection against agent percutaneous toxicity and
other necessary operational requirements.
 Animal data indicate that there is not a significant difference in HD-induced skin damage between
males and females; additionally, there do not appear to be substantial differences in cutaneous
response on the basis of race (e.g., dark versus light skin).
 The most significant source of variation in susceptibility to percutaneous absorption of CW agents
and their simulants is regional variation, relative to body site and skin thickness. Thus, selection
of appropriately protective CPE designs and materials based on differential body region
susceptibility to agent vapor exposures is appropriate.
 Assuming full-face protection, functional impairment will more rapidly follow from CW agent
vapor exposure to the groin and scrotal area than from any other body region. This finding is
particularly critical for consideration of operationally adverse exposures to agent sulfur mustard
(HD).
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 Nerve agents are non-irritating to the skin, and generate no cutaneous injuries. Biomarkers for
these agents may be used in conjunction with CPE permeation tests.
 Existing military percutaneous vapor toxicity estimates are not appropriate or adequate for
assessment of CPE to be worn by the civilian workforce. Specifically, effects at the concentration-
time cumulative exposure toxicity estimates for expected severe effects in 50% of the exposed
population [ECt50 (severe)] are too severe. The 50% threshold effect [ECt50 (threshold)] levels
represent more reasonable health endpoints, but are still effect levels for 50% of those exposed, as
opposed to levels protecting the majority (if not all) of the exposed population. In addition,
existing estimates alone neither address database gaps and uncertainties, nor, more importantly,
body region variation in absorption and susceptibility.
 Existing percutaneous toxicity data do not comprehensively support any clear, compound-specific,
procedure for extrapolating or adjusting ECt50 (threshold) levels to lower population-effect
percentages. The most reasonable approaches consider chemical- and effect-specific relationships.
 The state of the modeling tools presently available for percutaneous toxicity estimation is such
that discrimination cannot be made between concentrations of concern for exposure durations
between 30 and 50 min.
RECOMMENDATIONS
 Selection of appropriately protective CPE designs and materials should be based on systems tests
which focus on effective protection of the most vulnerable body regions (e.g., the groin area) as
identified in this analysis.
 A range of agent-specific cumulative exposures (Cts), bounded by the Ct for percutaneous vapor
estimated minimal effect (EMEpv) and the threshold ECt01 estimate (see Table ES-1), can be used
as decision criteria for CPE acceptance in conjunction with weighting consideration towards more
susceptible body regions.
 Assumptions of exposure duration used in CPE certification should consider that each agent-
specific percutaneous vapor cumulative exposure Ct for a given endpoint is a constant for
exposure durations between 30 min and 2 hours.
Table ES-1. Recommended CPE percutaneous vapor toxicity test ranges for nerve
agents (GA, GB, GD, GF, VX) and sulfur mustard (HD) (units in mg-min/m3)
Agent
Upper end of range:
ECt01 (threshold) est.a
Lower end of range: b
Est. min. effect Ct (EMEpv) c
GA 685 333
GB 411 180
GD 123  45
GF 103  45
VX  4.1  4
HD (hot temp.)  4.1  3
a Based on probit extrapolation of ECt50 (threshold) from Grotte and Yang 2001 (see Table 5 in
this report).
b For susceptible body regions, e.g., groin, scrotal area.
c See Table 4 of this report for basis and derivation.
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ABSTRACT
Percutaneous vapor toxicity guidelines are provided for assessment and selection of chemical
protective ensembles (CPEs) to be used by civilian and military first responders operating in a
chemical warfare agent vapor environment. The agents evaluated include the G-series and VX nerve
agents, the vesicant sulfur mustard (agent HD) and, to a lesser extent, the vesicant Lewisite (agent L).
The focus of this evaluation is percutaneous vapor permeation of CPEs and the resulting skin
absorption, as inhalation and ocular exposures are assumed to be largely eliminated through use of
SCBA and full-face protective masks.
Selection of appropriately protective CPE designs and materials incorporates a variety of test
parameters to ensure operability, practicality, and adequacy. One aspect of adequacy assessment
should be based on systems tests, which focus on effective protection of the most vulnerable body
regions (e.g., the groin area), as identified in this analysis. The toxicity range of agent-specific
cumulative exposures (Cts) derived in this analysis can be used as decision guidelines for CPE
acceptance, in conjunction with weighting consideration towards more susceptible body regions. This
toxicity range is bounded by the percutaneous vapor estimated minimal effect (EMEpv) Ct (as the
lower end) and the 1% population threshold effect (ECt01) estimate.
Assumptions of exposure duration used in CPE certification should consider that each agent-specific
percutaneous vapor cumulative exposure Ct for a given endpoint is a constant for exposure durations
between 30 min and 2 hours.

11.  INTRODUCTION
The U.S. Army Center for Health Promotion and Preventive Medicine (USACHPPM) provides health
and preventive medicine support to a variety of U.S. Army and U.S. Department of Defense (DoD)
agencies by conducting health-risk assessments of chemical exposure scenarios. In addition, as the
agency that directly supports the mission requirements of the Army Office of the Surgeon General, the
USACHPPM identifies or, when necessary, develops, health guidelines and exposure limits for
military-specific chemicals. Military-unique chemicals (such as the nerve and vesicant warfare agents)
are military–unique and have historically not been considered to pose substantial civilian or civilian
workforce hazards. As a result, civilian Federal agencies have provided little guidance relative to these
compounds. Concern over scenarios involving potential civilian exposures, however, has increased in
recent years. Consequently, various civilian Federal agencies have begun to coordinate or partner with
experienced U.S. Army personnel and contractors in efforts to develop and identify appropriate
civilian and worker guidelines, procedures, and associated resource requirements needed for response
to a potential chemical terrorist event.
One such example is an ongoing partnership among the U.S. Army Soldier and Biological Chemical
Command (SBCCOM), the Centers for Disease Control and Prevention (CDC), the National Institute
for Occupational Safety and Health (NIOSH), the National Institute of Standards and Technology
(NIST), and the National Institute of Justice (NIJ). This partnership is developing standards and
guidelines for selection of appropriate personal protective equipment for use by civilian and/or
military emergency workers responding to chemical, biological, radiological, or nuclear incidents.
Recent history has generated a heightened awareness of resource requirements needed for appropriate
response to a potential chemical terrorist event. Previous work and public meetings on this topic have
considered respiratory protection standards and guidelines (67 FR 38127, 31 May 2002 and 67 FR
61108, 27 Sep 2002; USDHHS 2002a, b). The USACHPPM has participated in this effort, and
coordinated the technical contract support provided by research staff of Oak Ridge National
Laboratory (ORNL) Life Sciences Division. The USACHPPM concurs with the recommendations of
this report from the Army’s medical perspective relative to toxicity guidelines for the assessment and
selection of clothing ensembles designed to protect emergency responders against percutaneous
exposures to vapors of nerve and vesicant chemical warfare agents. This report is provided for
consideration to ongoing partnerships as well as other agencies and organizations that may be
addressing similar issues.
22.  STATEMENT OF PURPOSE
The principal objective of this report is to summarize and recommend toxicity guidelines for selection
of chemical protective ensembles (CPEs) to be used by civilian and military first responders operating
in an environment containing vapors of either nerve or vesicant chemical warfare agents. While this
analysis recognizes that agent mixtures or multiple agents may be present in some threat
environments, the current evaluation addresses potential exposures to single agents only. The agents
under consideration include the G-series nerve agents and nerve agent VX; and the threat vesicant
agents sulfur mustard (agent HD) and, to a lesser extent, Lewisite (agent L). Levinstein mustard (agent
H; approximately 70% bis 2-chloroethyl sulfide and 30% higher molecular weight polysaccharides) is
not specifically addressed in this assessment. Nevertheless, it is reasonable to assume that guidelines
developed for percutaneous exposure to vapors of distilled sulfur mustard (agent HD; 100% bis
2-chloroethyl sulfide) would be protective against exposures to Levinstein mustard. The focus of this
evaluation is percutaneous vapor permeation through CPEs and exposure through the skin. It is
assumed that first responders in an agent vapor atmosphere will be wearing SCBA with full-face
protection. As a consequence, the eyes, nose, and mouth, as well as adjacent facial skin would be
protected from vapor contact; therefore no inhalation or direct eye vapor exposure is assumed.
Exposures to agent liquids, aerosols or mixtures are not addressed by this evaluation but may be
considered at a later date.
33.  BACKGROUND
3.1 EVALUATIONS OF CHEMICAL WARFARE AGENT PROTECTIVE
CLOTHING
During the U.S. history of offensive and defensive research programs evaluating chemical warfare
agents, a number of chemical protective clothing studies have been performed. One of the largest and
most extensive took place in the 1940s under the auspices of the Office of Scientific Research and
Development (OSRD), and was conducted by two OSRD divisions; the National Defense Research
Committee, and the Committee on Medical Research. These human-subject studies were the subject of
the Institute of Medicine (IOM) report Veterans at Risk: The Health Effects of Mustard Gas and
Lewisite (IOM 1993). The literature review of skin exposures to the vesicant agents sulfur mustard and
Lewisite, and the characterization of toxic response contained in this volume, is both extensive and
well researched. This IOM evaluation provides an excellent compilation that is useful to the current
analysis and points out that there are no good experimental data to indicate substantial differences in
cutaneous response on the basis of pigmentation associated with race [e.g., dark (Negro) versus light
(Caucasian) skin] when skin is exposed to injurious concentrations of sulfur mustard. Of greatest
significance is the site of skin exposure and skin thickness at that site; cutaneous response differences
between individuals are no greater than those differences observed for different body regions of the
same individual (IOM 1993).
A standing committee (Standing Committee on Program and Technical Review of the U.S. Army
Chemical and Biological Defense Command) of the National Research Council Board on Army
Science and Technology has performed a technical assessment of the Man-in-Simulant Test (MIST)
program (NRC/BAST 1997). This evaluation makes a number of recommendations regarding the
methods and logic of testing chemical protective ensembles, all of which are applicable to the current
evaluation, and which will be incorporated into the present analysis. A key observation made by the
Standing Committee was that the Army had heretofore “not established specific requirements for the
chemical protective qualities of its ensembles” in part because “test results (protection factors) have
never been correlated with biological endpoints,” particularly with regard to the known variations in
anatomic regional sensitivity to chemical warfare agents. As a consequence, the Standing Committee
considered that developers of chemical protective ensembles have not previously been able to
determine “how much protection is enough” (NRC/BAST 1997).
It is also noted that some weighting factor methods have been used to estimate average cumulative
permeation of nerve and mustard agent over an entire protective ensemble for an average elapsed time
(Belmonte 1998). The Expert Assistance (Equipment Test) Program has applied this latter method
during recent tests of protective clothing for the U.S. Army Soldier and Biological Chemical
Command (SBCCOM) Program Director for Domestic Preparedness.
3.2 RECOMMENDATIONS OF THE MAN-IN-SIMULANT (MIST) REPORT
(NRC/BAST 1997)
As previously noted, the Standing Committee on Program and Technical Review of the U.S. Army
Chemical and Biological Defense Command of the National Research Council Board on Army
Science and Technology performed and published a technical assessment of the Man-in-Simulant Test
(MIST) program (NRC/BAST 1997). Among their several tasks was (1) the preparation of a review of
the test methods for the MIST program, (2) an evaluation of the use of biological markers to predict
signs and symptoms associated with chemical warfare agent exposure, and (3) an examination of
4methyl salicylate (MeS) as a suitable simulant for MIST evaluations. Recommendations made by the
Standing Committee to the Chemical and Biological Defense Command (CBDCOM; and by
extension, to its successor agency the Soldier and Biological Defense Command, SBCCOM) are not
unique to the MIST program for evaluating chemical protective ensembles (CPEs), and are highly
applicable to the present analysis.
A general recommendation of the Standing Committee was the need for “a clear approach to
establishing physiologic endpoints for protective ensemble testing.” The current initiative will assist in
meeting that need.
3.2.1 General Test Protocols
The NRC Standing Committee found that the MIST test protocol for examining CPEs would be
improved by the addition of a preliminary screen that would eliminate those designs and individual
ensembles exhibiting gross defects or breaches. The application of such a screening step to any
program (not just MIST) of ensemble evaluation would allow greater efficiency, statistical power, and
focus of scarce resources on appropriate systems tests.
3.2.2 Use of Biomarkers
The selection of cholinesterase inhibition as a biological marker for considering percutaneous regional
variation to CW agent exposure was commended as a sound and innovative approach, but one that
should not be used to estimate HD absorption. Compliance with the recommended testing and
monitoring protocol development identified by the Standing Committee (NRC/BAST 1997) would
resolve the Committee’s reservations regarding the body region hazard analysis approach; e.g.,
establishing the relationship between ChE activity inhibition and nerve agent absorption through the
skin; the relationship between percutaneous absorption of agent liquid and vapor; accounting for the
“functional impairments” arising from sulfur mustard-induced lesions on sensitive body regions (groin
and scrotal areas); and accounting for individual variations in sensitivity. There was no Standing
Committee criticism of the relational comparison of regional susceptibility represented by body region
hazard analysis.
3.2.3 Use of Methyl Salicylate (MeS) as a Simulant for CPE testing
The Standing Committee considered MeS to be an appropriate simulant for estimating agent transport
into CPEs, but questioned using the results for making “biological interpretations” regarding CW
agents. Please note that the studies of Riviere et al. (2001) and Duncan et al. (2002) were performed in
the years following publication of NRC/BAST (1997), and members of the Standing Committee
would not have had access to these more recent data comparing MeS and agent absorption through the
skin of swine.
54.  SUMMARY OF LITERATURE FINDINGS
To further ongoing efforts in the development of updated standards for personal protective ensembles
suitable for use by civilian and military first responders in a chemical warfare agent environment, the
percutaneous toxicity of selected vesicants and nerve agent vapors has been examined. This memo
report summarizes and recommends concepts appropriate as decision criteria for selection of candidate
protective ensembles. This analysis assumes that first responders in an agent vapor atmosphere will be
using, and wearing, SCBA with full-face protection. As a consequence, the eyes, nose, mouth and skin
of the face would be protected from vapor contact, and no inhalation or direct eye vapor exposure is
assumed. The key issues addressed by this evaluation include: (1) whether the CWA is damaging to
the tissue at the site of contact; (2) the relevance of body region variation in absorption and
susceptibility to agent toxicity, and (3) the determination of agent-specific toxicity criteria to be used
in chemical protective suit penetration tests.
4.1 EFFECTS OF DERMAL EXPOSURES
4.1.1 Nerve Agents
“Nerve” agents are so named as a consequence of their anticholinesterase properties and subsequent
adverse effects on both smooth and skeletal muscle function as well as the central nervous system.
Nerve agent exposure also generates non-cholinergic effects, but their significance to the development
of known clinical signs and symptoms has not been characterized. Nerve agents are non-irritating to
the skin and generate no cutaneous injuries. The agents of concern for the present analysis are GA
(tabun), GB (sarin), GD (soman), GF, and VX.
The earliest signs of dermal exposure are local, and include increased sweating and muscular
fasciculations at the exposure site; these first effects may not be apparent for multiple hours post-
exposure (Sidell 1992, 1997). With increasing exposure and absorption, systemic effects such as
nausea, vomiting, diarrhea and weakness are manifested; in cases of severe exposure, effects may
progress to loss of consciousness, convulsions, paralysis, seizures, and respiratory arrest without
manifestation of the intervening mild-to-moderate effects of localized sweating, etc. (Sidell 1992,
1997; Munro et al. 1994). Percutaneous vapor concentrations needed to produce adverse effects are
significantly greater than inhalation vapor concentrations necessary to produce the same endpoint.
For example, the estimated human LCt50 for agent GB vapor inhalation exposure is 35 mg-min/m3,
while the estimated human LCt50 for GB percutaneous vapor exposure is 12,000 mg-min/m3 (Grotte
and Yang 2001).
4.1.2 Vesicant Agents
The vesicant agent sulfur mustard (agent HD) is an alkylating compound and, as such, readily reacts
with components of DNA, RNA and proteins. The chemical modifications that various biological
molecules undergo through alkylation can result in severe disorganization of normal cell function. As
a consequence, sulfur mustard is considered a cell poison, and is particularly toxic to mitotic cells. The
skin epithelium is an important target because of its proliferating basal cell layer, although sulfur
mustard produces cellular necrosis in any exposed cells at sufficient concentration. The biological
activity of HD is characterized by a latent period of hours to days, and may be followed by
inflammation, blistering, and local necrosis (depending on agent concentration and exposure duration).
Toxicological effects are local at the point of agent contact with the skin, and begin to manifest
(depending on exposure concentrations) within approximately 2–3 hours post-exposure (Dixon and
6Needham 1946; McNamara et al. 1975; Papirmeister et al. 1985, 1991; Smith and Dunn 1991; Watson
and Griffin 1992; Smith 2002). The earliest manifestation is usually an itching rash at the point of
contact, which may progress to swelling and erythema, and (sometimes large) blisters. Blisters are
relatively painless for several days, but after 5–6 days, the pain becomes severe upon exposure to air
or on contact; sensitivity of the blistered area can persist for weeks. Ulceration of the blister may or
may not develop, but progression to an ulcer may require weeks to heal. As exposure to sulfur mustard
also generates immunosuppression, infection of the blistered or ulcerated areas can be problematic.
The severity of skin lesions experienced by exposed individuals is influenced by a number of factors
independent of the exposure concentration, including anatomic and individual differences in skin
sensitivity, skin thickness, ambient temperature, and amount of sweat on the skin (Watson and Griffin
1992; IOM 1993). Animal (guinea pig) experiments with same-site exposure to sulfur mustard vapor
indicate that there are no significant discrepancies in severity of skin damage between males and
females (Wormser et al. 2002). Evidence indicates that severe acute exposure is causal for increased
pigmentation and depigmentation of exposed skin; such exposures can also lead to chronic skin
ulceration, scar formation and the latent development of cutaneous cancers. It is thought that chronic
exposure to minimally toxic (or subtoxic) doses could lead to abnormalities in skin pigmentation and
cutaneous cancer (IOM 1993).
The vesicant agent Lewisite (L) is also a cellular poison, and reacts by altering and inactivating critical
cellular enzyme systems. In marked contrast to sulfur mustard, Lewisite exposure is characterized by
prompt onset of pain and/or stinging or burning sensations; necrosis is early and complete. Erythema
is “immediate” (Smith and Dunn 1991), followed by the production of vesicles that coalesce to form
larger blisters in approximately 2-3 hours (Goldman and Dacre 1989; Smith and Dunn 1991). Larger
exposures result in agent penetration through subcutaneous tissue to muscle, with associated edema
and necrosis (IOM 1993). In general, the cutaneous injuries of Lewisite exposure resemble those of
HD, but develop more rapidly.
4.2 ASSESSMENT OF REGIONAL SKIN VARIATION IN ABSORPTION;
SUSCEPTIBILITY BY ANATOMIC SITE
Numerous studies of dermatological disease treatment, transdermal drug delivery and the health
hazards of contaminant exposure have documented site-specific body region differences in
percutaneous absorption. Such regional variation is well known in humans and a number of animal
species, particularly for pesticides used in agriculture (Wester and Maibach 1985,1989; Guy and
Maibach 1985; Maibach et al. 1971; Moody and Franklin 1987; and others). A number of the
pesticides for which regional variation has been determined are organophosphates, which exhibit the
same anticholinesterase properties as nerve agents. As a consequence, the findings of regional
variation studies performed with commercial organophosphates are relevant to the current analysis for
nerve agents.
In vivo human studies of percutaneous absorption for the commercial organophosphorous insecticides
malathion and parathion determined that the skin of the genital (scrotal) area exhibited a high
penetration index, followed by the skin of the trunk and head (intermediate), and skin of the legs and
arms (Maibach et al. 1971). Additional comparisons of scalp to forearm or forehead to forearm
absorption of malathion and parathion indicates that OP pesticide absorption through the skin of these
two regions of the head exceeds that of the forearm by an approximate factor of 4 (Wester and
Maibach 1989).
74.2.1 Nerve Agents
Most studies characterizing regional variation in permeability to nerve agents have been performed
with liquid agent VX. The single percutaneous vapor exposure study in humans is the work
documenting in vivo VX vapor exposures to the unclipped human arm or forearm published by
Cresthull et al. (1963).
It is acknowledged that the chemical and physical properties of agent VX differ from those of the
G-series nerve agents (Sidell 1997; Opresko et al. 1998; Munro et al. 1994, others) and that the agent-
specific dose to attain the same endpoint may thus differ. Nevertheless, it is reasonable to assume that
the relative differences in agent absorption exhibited between and among skin anatomic sites would be
similar for all the nerve agents of interest, irrespective of agent-specific chemical and physical
properties.
For a limited range of sublethal doses (5-25 g/kg) of VX applied to 19 intact and equal-area skin sites
on male human volunteers, Sim and Stubbs (1960) and Sim (1962) found that the head and neck areas
exhibited the greatest skin absorption rates (“the most sensitive”) as determined from serial blood
cholinesterase determinations (RBC, whole blood and plasma cholinesterase) and associated evidence
of clinical signs and symptoms. The head and neck areas tested included the back of the neck,
forehead, top of the head, cheek, and ear. Sim (1962) observed that these critical areas required the
most effective skin protection. Only slightly less “sensitive” than the head and neck areas were the
groin, armpits and the area behind the knee (Table 6, p. 29, Sim 1962). The least permeable skin sites
tested were those of hand, foot, knee (front) and elbow (exterior). Similar results were reported in the
adjunct in vivo human percutaneous body region study of VX liquid performed by Feinsilver et al.
(1965).
Craig et al. (1977) estimated the dermal absorption of liquid VX through the skin of the cheek and
volar forearm of human volunteers at a range of environmental temperatures ranging from 18C to
46C; the amount of VX absorption was estimated from the observed degree of RBC-cholinesterase
inhibition at various time periods post-exposure. At 3 hours post-exposure, the site differences in skin
absorption were approximately 10-fold, with the skin of the cheek being more permeable, regardless
of temperature. For each skin site, differences in estimated VX absorption also varied approximately
10-fold over the temperature range (–18C to 46C) evaluated. The Craig et al. (1977) study also
provided evidence that the skin can act as a storage depot for VX, with agent transfer from this depot
promoted by increasing ambient temperature.
Duncan et al. (2002) have performed in vivo regional variation studies of liquid VX absorption on
specific skin sites of domestic swine, a species with skin permeability similar to that of humans
(Bartek et al. 1972; Dick and Scott 1991). Agent VX absorption was estimated by determination of
blood cholinesterase (ChE) activity measured at various times post-exposure and expressed as a
percentage of the control ChE activity. “Dramatic” site dependence was displayed in the rates and
levels of ChE inhibition following same-dose topical application to skin of the ear or epigastrium. Of
the two sites compared, the skin of the ear is far more permeable and allows a larger systemic dose to
be delivered over a shorter time period (Duncan et al. 2002). The Duncan et al. (2001) work
demonstrates that the total effective systemic dose is the collective result of independent exposures
and consequent absorption from separate body regions through a process such as described by body
region hazard analysis (please see NRC/BAST 1997 for background information on body region
hazard analysis).
A number of available studies examining nerve agent percutaneous exposures to laboratory animals
and humans add to the general knowledge of topical nerve agent exposures, but do not specifically
8evaluate regional variation. Included are the excised-tissue and in vivo guinea pig studies of liquid
agent decontamination by van Hooidonk et al. (1983), the in vivo clipped rabbit abdominal skin
penetration studies of liquid GB by Griesemer et al. (1958), the in vivo clipped rabbit abdominal skin
penetration studies of GB vapor by McPhail and Adie (1960), the extensive review of animal literature
by van Hooidonk (1978), and the in vivo VX vapor exposures to the unclipped human arm or forearm
published by Cresthull et al. (1963).
4.2.2 Vesicant Agents
Body region variation in skin injury following exposure to vapors of sulfur mustard agent was evident
during treatment of casualties during World War I (Gilchrist 1928) (Table 1).
The incidence of percutaneous injuries (excluding those to the eyes, face and respiratory tract, which
under the current scenario would be protected with face and respiratory protection) in 6980 WW I
casualties ranged from high values of 42.1% and 23.9% for the scrotum and anus, respectively, to
relatively low values of 4.3% and 1.5% for the hands and feet, respectively. These operational data for
unprotected military personnel indicate that the most vulnerable (dermal) areas to the vesicant action
of sulfur mustard are not only moist and warm, but are also characterized by relatively thin skin
(Smith and Dunn 1991; IOM 1993; Papirmeister et al. 1991).
During WWII, human military subjects participated in
exposure chamber tests of treated clothing and respiratory
protection devices under various concentrations of HD vapor
(Heinen, et al. 1945; see also App. D “Excerpts from
Chamber Tests with Human Subjects I, II and IX. Naval
Research Laboratory (NRL) Reports Nos. P-22008 and
P-2579” from IOM 1993). Heinen et al. (1945) point out that
“the scrotal region was the most vulnerable area of the body”
to sulfur mustard agent vapor, “and would be the most
important area in the production of casualties,” particularly
when ambient temperatures were high ( 85F, or  29.4C).
As the NRL tests included experimental use of full-face
respiratory devices, distribution of the most severe injuries
from the Heinen et al. study is roughly coincident with that
exhibited by WWI casualties in Table 1, when eye and
respiratory tract protection are considered.
Note that IOM (1993) determined that the data presented in
Heinen et al. (1945), and other related NRL reports, were
collected without appropriate informed consent. Thus, the
study protocols of the NRL tests do not conform to accepted
guidelines concerning participation of human volunteers in
research.
The Textbook of Military Medicine volume addressing
chemical warfare agents (Sidell et al. 1997) generally concurs
with the earlier characterizations of parameters governing skin susceptibility, and states that the
“threshold amount of mustard vapor required to produce a skin lesion … varies greatly depending on
… temperature, humidity, moisture on the skin, and exposure site on the body. Warm moist areas with
thin skin such as the perineum, external genitalia, axillae, antecubital fossae, and neck are much more
Table 1. Distribution of mustard gas
injuries on bodies of World War I
casualtiesa
Body part
Reported injuries
(%)
Eyes 86.1
Respiratory tract 75.3
Scrotum 42.1
Face 26.6
Anus 23.9
Back 12.9
Armpits 12.5
Neck 12.0
Arms 11.7
Chest 11.5
Legs 11.4
Buttocks 9.8
Abdomen 6.4
Thighs 6.0
Hands 4.3
Feet 1.5
a Percentage of mustard gas injuries to
various body parts in 6980 World War I
casualties (Gilchrist 1928; Blewett 1986).
9sensitive” (Sidell et al. 1997, p. 205). Data from casualties of the Iran-Iraq war are similar (Momeni et
al. 1992; Augerson 2000).
Smith (2002) also points out that the “sensitivity of the groin and the need for elimination, even when
wearing protective clothing, makes mustard injury in that area especially likely.”
Data reported by a number of investigators, including an early vapor cup in vivo study by Nagy et al.
(1946) on the skin of the human forearm, document the greater penetration of HD vapor at higher
temperatures (30–31°C compared to 21–23°C). General concurrence is noted from a less quantitative
in vivo study of mustard vapor exposures to the human forearm published in the 1920s (Temple 1923)
and performed at “winter” and “summer” ambient temperatures (“susceptibility of subjects was found
to be greater in summer”). McNamara et al. (1975) and Papirmeister et al. (1991) also point out that
both severity and “time to development” of mustard vapor lesions are influenced by humid, hot
weather (“increases the effects”).
Methyl salicylate (MeS) has long been considered an appropriate simulant for agent HD due to similar
physical properties (water solubility, vapor pressure, and molecular weight) and fabric penetration
characteristics, as well as its known safety for human topical use (Riviere et al. 2001). Further, its
rapid hydrolysis and metabolism to salicylic acid and derivatives in the body of mammals allows
ready monitoring of MeS in blood serum as a measure of systemic absorption (Duncan et al. 2002).
Recent studies comparing percutaneous absorption and skin deposition of HD to MeS in the isolated
perfused porcine skin flap has determined that the cutaneous disposition of HD and MeS are very
similar (Riviere et al. 2001). The Riviere et al. (2001) work demonstrates that MeS simulates the HD
dose acquisition process and strongly supports the use of MeS as a dermal simulant for agent HD
exposure and hazard assessment. Topical application of MeS to 4 skin sites (skin of the ear, perineum,
inguinal crease, epigastrium) on the domestic pig have identified the following rank order for MeS
permeation: ear > perineum > inguinal crease  epigastrium (Duncan et al. 2002). It is reasonable to
consider the rank order of permeation would be similar for agent HD in contact with these same skin
sites on the human body.
Lewisite, an organic arsenical with vesicant properties, is considered faster acting and more toxic than
sulfur mustard at equivalent doses (see review by Watson and Griffin 1992). Nevertheless, much less
is known about Lewisite than sulfur mustard regarding penetration through human skin (IOM 1993).
Literature review has not identified any regional variation studies specific to Lewisite (IOM 1993;
Watson and Griffin 1992). Until agent-specific data are available for Lewisite, it will be assumed that
the body region variation in Lewisite absorption is similar to that documented for sulfur mustard.
4.2.3 Body Region Variation in Susceptibility
Body region variation in percutaneous absorption of CW agents and CW agent simulants has been
documented with operational data from “live agent” use under battlefield conditions, the results of in
vitro and in vivo experiments with agents and simulants, and literature summarizing percutaneous
exposures to commercial organophosphorous pesticides. It is well understood that agent exposure at
specific body regions results in more rapid and more severe physiological effects such as apnea
(Duncan et al. 2002). In the case of the vesicant agent sulfur mustard (agent HD), a cell poison at the
point of contact, physical impairment is also a function of regional skin variation in that the
characteristic burns and blisters following HD exposure cause greater and more rapid debilitation
when they develop at susceptible body regions (groin, scrotal area). As mentioned above, available
literature supports the assumption of similar body region susceptibility following percutaneous
absorption to the “other” vesicant agent, Lewisite (see IOM 1993; Watson and Griffin 1992).
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The threat nerve agents under consideration (the G-series nerve agents GA, GB, GD, GF; and nerve
agent VX) are non-irritating to the skin and generate no cutaneous injuries. For these compounds,
body region variation in agent absorption governs identification of the critical body areas requiring the
most effective skin protection to prevent development of significant systemic effects.
There is much convergence in the literature identification of specific body regions most susceptible to
nerve and sulfur mustard agent absorption. It is acknowledged that the estimated agent exposure
values considered critical will vary according to any number of assumptions used in developing
exposure estimates. Nevertheless, the relative ranking of body region susceptibility provided by
application of the body region hazard analysis logic as reviewed by the NRC/BAST (1997) seems
sound. Further, while not absolute, the resulting ranking is supported by operational information on
effects generated in the field as well as the susceptibility of certain body regions to incapacitating
exposures at less than “battlefield”
concentrations (IOM 1993, others). The
NRC/BAST (1997) recommended that
validation testing of the body region
hazard analysis concept be performed via
direct agent vapor exposure
measurements with excised human skin.
Perhaps partial validation could be
attained in vivo with tests on the skin of
swine. But until such validation can be
performed, it seems prudent to employ
the logic of relative ranking in body
region variation as derived from
NRC/BAST (1997; Table 2-3, p. 22,
“Parameters for local body region hazard
analysis”) to estimate critical body
regions requiring the most effective
protection from operationally adverse
agent concentrations. A summary is
provided in Table 2. With application of
the current study assumption of protected
head and face (SCBA with full-face
protection), the scrotal, ear, scalp and
neck areas are the remaining critical
regions requiring the most effective
protection. The literature indicates that
the entire groin area is especially
susceptible to sulfur mustard injury and
should be considered equivalent in
sensitivity to the scrotal area.
Table 2. Estimated relative rank in susceptibility of body
regions to operationally adverse concentrations of CW
agents (derived from Table 2-3; NRC/BAST 1997) a,b
Body region VX b HD
Scrotum  1.0  1.0
Chin and neck  3.2  3.3
Ears  4.1  4.2
Cheeks and neck  4.3  4.4
Nape (back of neck) 15.4 15.7
Scalp (top of head)  6.8  6.9
Abdomen 19.9 20.4
Back 23.7 24.3
Arms (lower, volar) 25.0 25.6
Arms (upper, dorsum) 58.6 60.2
Legs (plantar, lower) 25.0 25.6
Legs (plantar, upper) 38.1 39.0
Legs (dorsum, lower) 58.6 60.2
Legs (dorsum, upper) 58.6 60.2
Knees (front) 63.8 65.4
a Ranking relative to scrotal dose in g/kg (VX; estimated to cause
70% depression in RBC-ChE) or scrotal cumulative exposure in mg-
min/m3 (HD; estimated to cause local severe burns), with value of 1
(scrotum) indicating most susceptible body region. Source: Fedele and
Nelson (1996) as cited in NRC/BAST 1997.
b Given the state and extent of existing percutaneous toxicity data, it
seems reasonable to assume that the relative ranking exhibited by
nerve agent VX would be shared by the G-series agents. Agent-
specific vapor concentrations considered operationally adverse would
vary per individual chemical and physical properties, etc.
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4.3 EXISTING TOXICITY CRITERIA
As this report is focusing on percutaneous vapor exposures, only those criteria relevant to the
percutaneous absorption of agent vapors are described here.
4.3.1 Acute Human Toxicity Estimates (NRC/COT 1997)
In 1996, The National Research Council Committee on Toxicology established the Subcommittee on
Toxicity Values for Selected Nerve and Vesicant Agents to evaluate the scientific validity of proposed
military estimates of human toxicity for the chemical warfare agents GA, GB, GD, GF, VX and HD.
The Subcommittee was chaired by Dr. Loren Koller, DVM, and was charged with examining the
decision protocols and data quality for a variety of acute toxicological endpoints (ranging from mild to
lethal) and different exposure routes, the derivation methods, and the underlying assumptions on
which the derivations were based. The Subcommittee findings and recommendations were published
in their summary report Review of Acute Human-Toxicity Estimates for Selected Chemical-Warfare
Agents, in 1997 (NRC/COT 1997).
In general, the Subcommittee noted the limited database and recommended that the Army establish an
expert panel to determine a research strategy for addressing key data gaps. The Subcommittee also
recommended that human toxicity estimates be based on more current decision logic such as structure-
activity relationships, uncertainty factors and experimental results with in vitro systems. However, the
Subcommittee recognized that “best estimates” were needed to protect military personnel, and
therefore made detailed and agent-effect-specific Ct recommendations for inhalation (vapor) and
percutaneous (vapor and liquid) exposures. The evaluation indicated that some of the proposed
military estimates were scientifically valid, others could only be considered interim pending additional
data, some should be lowered, while others should be raised. Because of the data limitations and fact
that the estimates were designed for healthy male soldiers, the Subcommittee also stated that the
proposed human-toxicity estimates “must not be used for civilians.” (NRC/COT 1997).
4.3.2 Current Military Estimates (Grotte and Yang 2001)
As a result of the NRC/COT (1997) report, the DoD is pursuing initiatives to address scientific data
gaps. However, as the military has ongoing needs for various applications of CW agent toxicity
criteria, the Office of the Assistant to the Secretary of Defense for Chemical and Biological Defense
endorsed a policy in December 2001 (OASD-CBD 2001) that provides interim toxicity estimates for
application to threat and CONOPS planning, active and passive defense, counter-force operations, and
other military needs where the impact of chemical weapon use is critical. These interim toxicity values
are documented in a report by the Institute for Defense Analysis (IDA), referred to as the “IDA
report.” The IDA report (Grotte and Yang 2001) proposes ECt50 (threshold) and ECt50 (severe)
cumulative exposures estimates (units of mg-min/m3) for acute effects and short-term (30-min)
percutaneous exposures (see Table 3); the report indicates that the accuracy of extrapolations to
exposure times beyond two hours is unknown. As defined in Grotte and Yang (2001), the
percutaneous vapor “threshold” for nerve agents refers to “a slight ChE inhibition,” and is thus a
systemic effect endpoint. Threshold effects for HD are defined as “the midpoint of the dosage range at
which effects begin to occur in the sample population” (Grotte and Yang 2001, page 7, footnote to
Tables 1-6); however, threshold effects are not specifically characterized.
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These percutaneous vapor values
are for unclothed persons (70-kg
males) only. For nerve agents, it
is assumed that soldiers are
masked and possess full eye
protection (Grotte and Yang
2001). Grotte and Yang (2001)
are silent on the topic of body
region variation in skin
absorption and susceptibility.
Thus it is not clear if the above
estimates of “threshold”
cumulative exposure are
sufficiently protective for
sensitive body regions, such as
the groin and scrotum (especially
for sulfur mustard). However,
because the IDA values are
reported to be for unclothed
persons, (and assuming that
unclothed means complete
nudity), inference indicates that
the IDA estimates would
incorporate exposure to the most
susceptible body regions. Therefore, the assumption could be made here that the IDA values are
protective for the most susceptible body regions.
Table 3. Existing interim military percutaneous vapor toxicity
values for nerve agents (GA, GB, GD, GF, VX) and sulfur mustard
(HD) (units in mg-min/m3)a
Agent
ECt50
(severe)
ECt50
(threshold)
GA 12000 2000
GB  8000 1200
GD  2000  300
GF  2000  300
VX  25  10
HD (moderate temp.)  500b  50
HD (hot temp.)  200b  25
a J. H. Grotte and L. I. Yang, Report of the Workshop on Chemical Agent
Toxicity for Acute Effects, Institute for Defense Analyses, 11-12 May, 1998.
IDA Document D-2176, Institute for Defense Analyses (IDA), Alexandria, Va.
(June 2001). For 30-min exposures to unclothed 70-kg male soldiers and acute
effects following vapor exposure to undiluted agent in military scenarios; not
for female military personnel or civilians, or exposures to modified versions of
these agents. For nerve agents, percutaneous exposures are for masked soldiers
with eye protection. “Threshold” for nerve agents refers to “a slight ChE
inhibition.” Threshold effects for HD are defined as “the midpoint of the
dosage range at which effects begin to occur in the sample population”;
however, specific effects are not characterized.
b Vesication.
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5.  EVALUATION AND DISCUSSION
5.1 DETERMINING TOXICITY GUIDELINE CRITERIA FOR CIVILIAN CPE
The purpose of this evaluation is to identify criteria for evaluating CPEs to be used by the civilian
workforce during domestic/homeland defense response activities. The intent behind such criteria
should be consistent with general occupational health standards. Specifically the Occupational Safety
and Health Act of 1970 [Section 2(b)] cites the Act’s purpose to “assure as far as possible every
working man and woman in the Nation safe and healthful working conditions … by setting standards
that [Section 6(b)(5)] most adequately assures, to the extent feasibly possible, on the basis of best
available evidence that no employees will suffer material impairment of health”(U.S. Congress 1970).
Even so, 100% protection of the worker population against all effects is not always considered feasible
given the wide degree of variation in susceptibility, as demonstrated by various occupational threshold
limit values (TLVs) (ACGIH 2000). Threshold Limit Values are described as concentrations to which
“nearly all workers may be exposed … without adverse effects” (ACGIH 2000). With this in mind, the
goal of the present analysis is to provide scientifically based minimal effects levels that are reasonably
protective of the civilian workforce against any adverse effect.
As indicated previously, NRC/COT (1997) pointed out that the human data forming the basis for the
military toxicity estimates (as later presented in Grotte and Yang 2001) varied both in quality and
degree of confidence warranted for such estimates. An example is the estimate for sulfur mustard
(HD); the NRC/COT (1997) judged that the human data forming the basis for the threshold estimate
were not sufficiently characterized in the source report (PCS 1946) “to allow for full evaluation” and
confidence. The severe-effects estimates for sulfur mustard were clearly derived from “man-break”
data for skin burns and blisters. “Man-break” tests were those deliberately designed to determine the
agent concentrations and exposure durations sufficiently injurious to make exposed individuals unfit
for duty. The NRC/COT (1997) reviewers considered that evaluation of experimental, low-vapor
concentration data would be required before adequate confidence in the estimates could be attained,
and recommended that percutaneous threshold ECt50 values (for both threshold and severe effects from
HD) should be considered interim values only until improved data were available. In addition, the
NRC/COT (1997) noted that the proposed estimates are limited to applications involving male military
personnel (excluding female military personnel and no civilians of either gender).
Given the caveats to existing toxicity estimates as described above, the current analysis considered a
number of alternatives by which to estimate a minimal effect level suitable for civilian emergency
workers, and to thus recommend a cumulative percutaneous exposure range over which CPE
ensembles could be evaluated. Because existing percutaneous toxicity data and estimates do not
comprehensively support any clear, compound-specific, procedure for estimating minimal effects,
some existing methods used for inhalation vapor toxicity estimation were considered for comparative
purposes. Ultimately, however, methods that address chemical- and effect-specific relationships, or
which consider agent-specific distributions (as defined by the probit slope) were determined to be
most defendable. The various methods developed and considered are outlined below:
5.2 METHODS EVALUATED TO ESTIMATE MINIMAL EFFECT LEVELS
5.2.1 Method A
It is known from NRC/COT (2001) that an LC01 can be approximated from an experimentally derived
LC50 when certain parameters can be met by the experimental data: all experimental exposure levels
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should have caused some lethality, there is a steep dose-response curve, and data characterizing
response at the lower part of the dose-response curve are available for examination. If these conditions
can be met, then the LC50 can be divided by a single specific factor (typically a factor of “3,” based on
knowledge that the average factor documented in the experimental literature for inhalation toxicity
experiments is approximately 2, with a 90th percentile of 2.9 and a 95th percentile of 3.5; range of 1.1
to 6.5) (NRC/COT 2001). However, this method has only been documented for the lethality endpoint;
there is no comparable approximation procedure of division by a single specific factor documented for
adjustment from ECt50 determinations. In addition, the NRC documents this method for vapor
inhalation only, and does not address percutaneous toxicity. Though this approach would to some
degree reflect agent- and endpoint-specificity, the required statistical and physiological basis for
application of this approach are not met for percutaneous toxicity estimates. Thus, Method A is not a
recommended or preferred approach, but is included here for comparison.
5.2.2 Method B
Another approach evaluated was to apply the standard default uncertainty factor (UF) for intraspecies
variability to respiratory toxicants in humans (equal to a value of “10”; NRC/COT 2001) to the ECt50
values from Grotte and Yang (2001) for the purpose of approximating a minimal effect level. The use
of uncertainty factors in estimating percutaneous toxicity endpoints is not well characterized, and the
literature review performed during the present analysis could find no precedent for such a procedure.
In particular, as has been previously noted in this analysis, there appears to be limited intraspecies
variability for percutaneous absorption. The critical source of variability is attributed to individual
differences in susceptibility relative to body site and skin thickness. For this reason, and because
Method B does not consider agent- or endpoint-specificity, this method is not a recommended or
preferred approach.
5.2.3 Method C
The third approach evaluated provides some degree of compound- and endpoint-specificity, and
maintains consistency with recent previous estimates for these agents (Grotte and Yang 2001). For
each chemical warfare agent under consideration, the IDA Report presents two values for
percutaneous ECt50; one each for “severe” and “threshold” effects. For the nerve agents, “severe”
effects are defined as “systemic, similar to lethal effects,” while “threshold” refers to “a slight ChE
inhibition.” For sulfur mustard agent HD, “severe” effects consist of “vesication,” while “threshold”
effects “are defined as the midpoint of a dosage range at which effects begin to occur.” The difference
in ECt50 values between “severe” and “threshold” results in a ratio that is both compound- and
endpoint-specific (e.g., for agent GA, the difference between “severe” and “threshold” from 12000 to
2000 mg-min/m3, results in a ratio of 6; see Table 3). This ratio is then applied to the threshold ECt50
as a means of estimating a minimal effect level (e.g., one-sixth of 2000 mg-min/m3 is 333 mg-min/m3,
rounded to the nearest whole number). Applying the same procedure for agents GB, GD, GF, VX and
HD results in the ratios and the percutaneous vapor “estimated minimal effect” or “EMEpv” Ct values
summarized in Table 4.
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Table 4. Percutaneous vapor estimated minimal effect (EMEpv ) toxicity values for nerve agents
(GA, GB, GD, GF, VX) and sulfur mustard (HD) (units in mg-min/m3) a ; Method C
Agent
ECt50
(threshold)a
Basis for ECt50
(threshold) effect
Ratio
threshold:
severeb
Est. min.
effectb Ct
(EMEpv)
GA  2000 ChE activity inhibition but no
performance degradation;
human datac
1: 6 333
GB 1200 Sweating, ChE activity
inhibition; human datac
1: 6.7 180
GD  300 Relative potency from GB datac 1: 6.7  45
GF  300 Assume GF equipotent to GD 1: 6.7  45
VX  10 <50% ChE activity inhibition;
extrap. from human exposure to
25.6 mg-min/m3; low
confidence in datac
1: 2.5  4
H/HD (L)d
(hot temperature)
 25 Less than Ct required to
generate mild erythema; human
datae
1: 8  3
a Grotte, JH and LI Yang, 2001. Report of the Workshop on Chemical Agent Toxicity for Acute Effects. Institute for
Defense Analyses, 11-12 May, 1998. IDA Document D-2176, Institute for Defense Analyses (IDA), 1801 N.
Beauregard St., Alexandria, VA (June 2001). For 30 min exposures to unclothed 70 kg male soldiers and acute effects
following exposure to undiluted agent in military scenarios; not for female military personnel or civilians, or
exposures to modified versions of these agents. For nerve agents, percutaneous exposures are for masked soldiers
with eye protection.
b Estimated from the ratio between severe and threshold percutaneous ECt50 values (see Table 3) for each agent as
presented in Grotte and Yang (2001); see text for logic and details.
c Effect evaluations from National Research Council, Committee on Toxicology (NRC/COT) 1997. Review of Acute
Human-Toxicity Estimates for Selected Chemical-Warfare Agents, Subcommittee on Toxicity Values for Selected
Nerve and Vesicant Agents, Committee on Toxicology, National Research Council. National Academy Press,
Washington, D.C.
d As stated earlier, until more agent-specific data become available, the current analysis assumes that toxicological
endpoints developed for vesicant agent HD will also apply to vesicant agent L (Lewisite).
e PCS 1946 as cited in Papirmeister et al. 1991. Threshold for non-disabling signs and symptoms in sulfur-mustard
exposed adult male military personnel is 50 mg-min/m3.
5.2.4 Method D
A fourth approach, which is also compound- and endpoint-specific, considers the application of probit
slopes to developing percutaneous vapor estimates for endpoints other than ECt50. As discussed
earlier, the Grotte and Yang (2001) report provided percutaneous toxicity values for several endpoints:
LCt50, ECt50 (threshold) and ECt50 (severe), rounded to the nearest associated power of 10, along with
the probit slope values (rounded to the nearest whole number). In the current analysis, standard
methods have been employed to extrapolate percentile values towards the lower end of the log-normal
ECt50 (threshold) distribution curve as a means to estimate minimal effects levels. Statistically, values
below the 16th percentile have low reliability, but such values are nevertheless useful for purposes of
comparative estimation. As a consequence, the 1 and 16th percentile estimates for ECt (threshold)
have been calculated for the G-series nerve agents, nerve agent VX, and vesicant agent HD as an
approach to estimating a minimal effect level. (See Table 5).
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Method D calculations were performed using the following assumptions concerning the ECt50 and the
probit slope:
1. That for any fixed variable for concentration, there was a corresponding random variable for
percent affected containing a probability distribution with a finite mean and variance.
2. That all of the determined percent affected were statistically independent from each other.
3. That the average value for percent affected is a straight-line function of concentration.
4. That the variances for concentration and percent affected were statistically equal.
5. That for any fixed value for concentration, there was a normal distribution for percent affected.
6. That the intercept used in the calculation was equivalent to the difference between the calculated
50% response and that provided in the IDA report.
The following limitations also apply to the calculated results:
1. The probit distribution was derived from a common error function derived from 50% adjusted to a
slope of 5.0.
2. A normally distributed population is assumed with the results sensitive to outlying points.
3. Most importantly, the frequency distribution of each point along the line becomes more
asymptotic as it approaches the extremes of the range. That is to say that in the probit range of 16
to 84% [those values associated with 1 standard deviation (SD)] the error in the line changes
gradually. Beyond this range, the error changes ever more rapidly (Kleinbaum et al. 1988). As a
consequence, the confidence limit in a 1% value is broad. Statistically, the most confidence in the
results would be for the interval between 16 and 84%.
Table 5. Comparison among estimates of percutaneous vapor minimal effects levels; Method A, B, C,
and D toxicity values for nerve agents (GA, GB, GD, GF, VX) and vesicants (H/HD and L)
(units in mg-min/m3)
Method D: probit
extrapolationse
Agent
ECt50
(threshold)a
Method A:
est. ECt01 [ECt50
(threshold)/3]b
Method B:
UF approach
[ECt50
(threshold)/10] c
Method C:
ratio-based
EMEpvCt d
ECt01
(thresh.)
ECt16
(thresh.)
GA 2000 667 200 333 685 1265
GB 1200 400 120 180 411  759
GD  300 100  30  45 123  205
GF  300 100  30  45 103  190
VX  10  3.3  1  4  4.1  6.8
H/HD (L)
(hot temp)
 25  8.3  2.5  3  4.1  11.7
a From Grotte and Yang (2001).
b Required statistical and physiological basis for application of this approach cannot be met for percutaneous toxicity
estimation. Not recommended or preferred.
c No agent- or endpoint-specificity. Not recommended or preferred.
d Compound- and endpoint-specific; maintains consistency with Grotte and Yang (2001). Recommended and preferred.
e Compound- and endpoint-specific; applies probit slopes of Grotte and Yang (2001) to estimate ECt01 percentile, which is
statistically unreliable. Useful for comparison with method C.
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5.3 SUMMARY OF METHODS EVALUATION
With full acknowledgement of the described limitations, it is nevertheless useful to compare various
estimates derived from the four methods (A, B, C, D) described above. It is particularly interesting to
note that all methods yield estimates of minimal effect levels that are within the same order of
magnitude. For all agents, the EMEpv (Method C) provided middle ground values for the range of
estimates. For threshold effects, the EMEpv Ct for G-agents is less than 50% of the probit-estimated
ECt01 and approximately four times less than the ECt16 (Method D), while the EMEpv for agent VX is
approximately equal to the estimated ECt01 (and approximately 60% of the ECt16). For sulfur mustard
agent HD, the EMEpv Ct for high temperatures (3 mg-min/m3) is only slightly less (and likely not
significantly so) than the estimated “high-temperature” ECt01 (4.1 mg-min/m3; though approximately
4 times less than the ECt16). Methods A and B, though the least rigorous and least preferred of the
approaches, exhibit relative consistency with the results from Methods C and D. This comparison
provides added confidence to the overall analysis.
Because they are bounded by the other estimates and are compound- and endpoint-specific, the EMEpv
Ct values derived from Method C are selected as the ‘best’ toxicity guideline criteria of those
examined for CPE testing. These toxicity guidelines provide protective criteria for the emergency
response user community in that they incorporate consideration of particularly susceptible body
regions. To provide a range of toxicity guideline criteria, such as to establish less stringent criteria for
assessing CPE protection of less susceptible body regions, the ECt01 (threshold) estimates derived
from Method D provide a reasonable high end of the minimal effect range.
5.4 EXPOSURE DURATION
In addition to estimating a minimal effect toxicity Ct, the concept of applying this toxicity estimate to
a specified duration of time was assessed. Grotte and Yang (2001) indicate that the percutaneous vapor
estimates summarized in their report are for 30-min exposures to individuals without clothing (nude),
and that “accuracy of extrapolation beyond 2 hours is unknown.” After examining the same parent
data set as utilized by Grotte and Yang (2001), NRC/COT (1997) documents assumptions of 30- to
50-min exposure durations and light clothing for percutaneous vapor exposure estimates (when
compared to Grotte and Yang 2001, values in NRC/COT 1997 are same or similar). It would appear
that the state of the modeling tools available for percutaneous toxicity estimation is such that
discrimination cannot be made between concentrations of concern for exposure durations between 30
and 50 min. Therefore, for a given endpoint and scenario, it may be reasonable to assume an agent-
and endpoint-specific constant Ct for exposure durations between 30 min and 2 hours. Further, this
constant Ct should be equal to the 30-min Ct for that agent and EMEpv. Thus, the 30-min EMEpv of
333 mg-min/m3 for agent GB would be equivalent to 11 mg/m3 for 30 min, or 5.6 mg/m3 for 60 min,
or 2.8 mg/m3 for 2 hours. The accuracy of extrapolations for exposure durations in excess of 2 hours is
unknown (Grotte and Yang 2001).
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6.  CONCLUSIONS
 Percutaneous vapor concentrations needed to produce adverse effects are significantly greater
than inhalation vapor concentrations necessary to produce the same effect (for nerve agents
especially, and sulfur mustard to a lesser extent). Thus, health-based inhalation and ocular toxicity
guidelines used to test adequacy of respiratory protection would be substantially protective for
percutaneous vapor effects from the same agent exposure. However, use of overly
protective inhalation and ocular toxicity criteria for CPE evaluation may unnecessarily limit
consideration of other critical CPE operational specifications. Application of separate toxicity
guidelines for percutaneous vapor absorption alone will ensure that CPE testing criteria include an
appropriate balance of protection against agent percutaneous toxicity and other necessary
operational requirements.
 The application of a preliminary ensemble evaluation screen to eliminate those designs and
individual ensembles exhibiting gross defects or breaches would allow greater efficiency,
statistical power, and focus on appropriate systems tests.
 Animal data indicate that there is not a significant difference in HD-induced skin damage between
males and females; additionally, there do not appear to be substantial differences in cutaneous
response on the basis of race (e.g., dark versus light skin).
 The most significant source of variation in susceptibility to percutaneous absorption of CW agents
and their simulants is individual body region variation, relative to body site and skin thickness.
Thus, selection of appropriately protective CPE designs and materials based on differential body
region susceptibility to agent vapor exposures is appropriate.
 With the operating assumption that responders in an agent vapor atmosphere will be wearing
SCBA with full-face protection, functional impairment will more rapidly follow from CW agent
vapor exposure to the groin and scrotal area than from any other body region. This finding is
particularly critical for consideration of operationally adverse exposures to the vesicant agent
sulfur mustard (HD).
 Other vulnerable body regions include the neck, scalp, axillae, and area behind the knee (See
Tables 1 and 2 of this report)
 Until more agent-specific data become available, toxicological parameters developed for vesicant
agent HD may apply to vesicant agent H (Levinstein mustard) and agent L (Lewisite).
 Nerve agents under consideration are non-irritating to the skin, and generate no cutaneous injuries.
Biomarker assessments for these agents as described in NRC/BAST 1997 may be used in
conjunction with CPE permeation tests.
 Existing military percutaneous vapor toxicity estimates (IDA Report of Grotte and Yang 2001) are
not appropriate for assessment of CPE to be worn by the civilian workforce. Specifically, effects
at the concentration-time cumulative exposure toxicity estimates for expected severe effects in
50% of the exposed population [ECt50 (severe)] are too severe. The 50% threshold effect [ECt50
(threshold)] levels represent more reasonable health endpoints, but are still effect levels for 50% of
those exposed, as opposed to levels protecting the majority (if not all) of the exposed population.
In addition, existing estimates alone neither address database gaps and uncertainties nor, more
importantly, body region variation in absorption and susceptibility.
 Existing percutaneous toxicity data do not comprehensively support any clear, compound-specific,
procedure for extrapolating or adjusting ECt50 (threshold) levels to minimal effect levels.
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However, four extrapolation methods developed and evaluated in the present analysis produce
estimates all within the same order of magnitude. The most reasonable approaches consider
chemical- and effect-specific factors as well as consideration of the agent-specific dose-response
curve as defined by the probit slope.
 The state of the modeling tools presently available for percutaneous toxicity estimation is such
that discrimination cannot be made between concentrations of concern for exposure durations
between 30 and 50 min. It is recommended that, for a given endpoint and scenario, the agent-
specific percutaneous vapor Ct be considered a constant for exposure durations between 30 min
and 2 hours.
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7.  RECOMMENDATIONS
Selection of appropriately protective CPE designs and materials includes a variety of test parameters
to ensure operability, practicality, and adequacy. One aspect of adequacy assessment should be based
on systems tests, with primary focus on effective protection of the most vulnerable body regions (e.g.,
groin and scrotal area) identified in the above analysis.
In conjunction with weighted consideration towards more susceptible body regions, the range of
agent-specific Cts (see Table 6) bounded by the estimated minimal effect (EMEpv Ct) level and the
threshold ECt01 extrapolated from Grotte and Yang (2001) can be used as toxicity guidelines for
evaluating and determining CPE acceptance. An example of how these toxicity guidelines may be
applied is provided for sulfur mustard (HD), the agent of most significant importance for this testing:
In challenge tests of CPE designs, permeation or breach in the groin area of vapor at a Ct greater than
the 3 mg-min/m3 EMEpv but less than the 4.1 mg-min/m3 threshold ECt01 estimate (for hot
temperature) over a 30-min exposure duration would be sufficient grounds for ensemble rejection. For
other less susceptible body areas (e.g., arms, legs, chest, etc), permeation below the 4.1 mg-min/m3
threshold ECt01 should be a minimum standard; i.e., exceeding the threshold ECt01 estimate in any test
for any body region should be grounds for ensemble rejection.
Assumptions of exposure duration used in CPE certification should consider that the agent-specific
percutaneous vapor Ct for a given endpoint is a constant for exposure durations between 30 min and
2 hours.
Table 6. Recommended CPE percutaneous vapor toxicity test ranges for nerve
agents (GA, GB, GD, GF, VX) and sulfur mustard (HD) (units in mg-min/m3)
Agent
Upper end of range:
ECt01 (threshold) estimatea
Lower end of range:b
est. min. effect (EMEpv Ct)c
GA 685 333
GB 411 180
GD 123  45
GF 103  45
VX  4.1  4
HD (hot temp.)  4.1  3
a Based on probit extrapolation of ECt50 (threshold) from Grotte and Yang 2001 (see Table 5
above).
b For susceptible body regions, e.g., groin, scrotal area.
c See Table 4 above for basis and derivation.
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